(PNET) 2/2 PR and pineal germ cell tumours 6/6 with four CR and two PR.
It is concluded that platinum-based chemotherapy has a beneficial effect on CNS tumours of the CNS, especially medulloblastoma, ectopic intracranial retino-blastoma and pineal germ cell tumours.
Patients and methods Twenty nine children and young adults who were treated at St Bartholomew's hospital during a seven year period were reviewed (table 1). All had malignant disease that could be evaluated. Staging evaluation was performed at the time of entry into the study and included CT head scanning, myelography, CSF studies and bone marrow aspiration. The median age of the patients was 12 years (range 2-32). The male to female ratio was 1 4: 1. Before chemotherapy, all patients had normal renal function and satisfactory haematological findings-with absolute neutrophil count > 1000/ml and platelet count > 100 000/ml. The The platinum dose was reduced by 33% if the total neutrophil count has been < 1000/ml or a platelet count < 50 000/ml during a previous course and if necessary the frequency of courses was decreased.
Results
Ofthe 29 patients, two received only one course of chemotherapy because of rapid clinical deterioration. Nine patients achieved a CR, 13 a PR, whilst one had stable and six had progressive disease (table 5) . Only six patients had no radiotherapy and, of the remaining 23 patients, 20 had irradiation after two courses of chemotherapy and were given further chemotherapy post-irradiation. The duration of response ranged from 2-48 months (mean 11). The subsequent radiotherapy may have increased the response duration, but response rates recorded here are for chemotherapy. In general, patients with a positive response showed clinical improvement before evidence of response on CT scan. Response criteria were applied to patients before radiotherapy was given. CR was observed in nine patients after four to six courses whilst a PR was seen in 13 patients after two to six courses (median 3). Significant improvement in most responders occurred after two courses (figs 1 and 2). There was no difference in duration of response between the two platinum derivatives, but there were differences in toxicity, which are discussed below. There was a higher response rate in patients with a medulloblastoma, a pineal germ 
TOXICITY
In general the toxicity encountered was tolerable. All patients experienced mild/moderate gastrointestinal upset (Grade 1-2)6 which could usually be controlled with sedative and anti-emetic therapy. Myelosuppression was tolerable though three patients had problems with thrombocytopaenia necessitating a reduction in carboplatin dosage and prolongation of interval between courses of therapy. There were no serious infectious complications and no significant persistent renal toxicity. However, two patients required a reduction of their cisplatinum dose in view of a fall in glomerular filtration rate (Grade 2 50-75% normal).6 Cisplatinum was discontinued after four courses in two patients who developed moderate audiotoxicity (high frequency hearing loss). Interestingly, two patients suffered exacerbation of fits, one of whom also had hyponatraemia with inappropriate ADH secretion after her first course of vincristine, etoposide and carboplatin. Further chemotherapy in these patients was not possible. Treatment was also discontinued in one girl, with a pineal germ cell tumour, who had respiratory complications which were thought to be related to bleomycin administration. In total five patients discontinued treatment, six patients had to have their dose decreased as a result ofeither haematological or renal toxicity.
Discussion
Cytotoxic levels of platinum are reached in the CSF within a short period after infusion into patients with a CNS tumour."' Khan, et al4 reported a favourable response of recurrent brain tumours to platinum products and several others have documented similar results.'8 Our review also confirms that certain CNS tumours respond to platinum-based chemotherapy.
These observations may be pertinent to the management of infants with such a tumour, in whom there is a strong case for initial chemotherapy and delayed radiotherapy.'4 Chemotherapy may also enhance the effects of radiotherapy or reduce the size of the tumour before surgery. Nephrotoxicity is well documented with platinum products and the potential enhancement of ototoxicity with radiotherapy9' can lead to marked hearing problems and the need to limit doses. Allen, et al' have shown carboplatin to be effective with less risk of renal and ototoxicity. In our review there were no significant septic haematological complications but neurological complications could be severe. One should be wary of treating patients who have had seizures because there is the risk of increasing intracranial pressure and cerebral herniation during chemotherapy.
Our numbers are small and therefore we cannot comment on whether patients who received radiotherapy had a greater magnitude of response and a longer overall duration of response. However, as seen in therapy. Some workers state that chemotherapy is the preferred treatment of primary or metastatic non-seminomatous germ cell tumours of the brain. 3 15 There are also reports of secondaries from shunt procedures and these should be easily treated if in a responsive histological group. '6 17 The therapeutic value of cisplatinum and carboplatin must be balanced against the risks of significant and irreversible toxicity. Carboplatin may be preferable where the inner ear is in the field of radiation, although following whole neuraxis radiotherapy reduction in red marrow tolerance may limit its use. This problem may later be resolved using growth factors. Carboplatin may induce responses in cisplatinum resistant disease.
As others have reported, ependymomas are poorly responsive compared to medulloblastoma, pineal germ cell tumours, PNET and ectopic retinoblastoma. Our response rate in medulloblastoma is similar to that reported by Walker and Allen.8 Platinum products should therefore be considered in the management of both primary and selected recurrent CNS tumours in childhood and further studies of pre-radiation platinum-based chemotherapy are currently in progress.
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